Sentry Investment Management LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,797 shares of the medical research company’s stock after acquiring an additional 1,484 shares during the period. Sentry Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $6,038,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Amalgamated Bank lifted its stake in Thermo Fisher Scientific by 57.0% in the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 2.1% during the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after acquiring an additional 977 shares during the last quarter. Americafirst Capital Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at $876,000. San Francisco Sentry Investment Group CA bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $1,451,000. Finally, Huntington National Bank raised its stake in shares of Thermo Fisher Scientific by 2.4% during the third quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock valued at $36,959,000 after acquiring an additional 4,655 shares during the last quarter. Institutional investors and hedge funds own 86.11% of the company’s stock.
A number of brokerages recently weighed in on TMO. Leerink Swann reissued an “outperform” rating and set a $200.00 target price (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. BTIG Research began coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Finally, Barclays lifted their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $220.50.
In other news, CFO Stephen Williamson sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,741 shares in the company, valued at $6,432,861.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The disclosure for this sale can be found here. Insiders sold 144,327 shares of company stock valued at $28,680,042 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (TMO) opened at $204.51 on Tuesday. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. The company has a market cap of $80,271.26, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 1.47 and a beta of 1.11. Thermo Fisher Scientific Inc. has a twelve month low of $151.74 and a twelve month high of $226.44.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the company posted $2.41 earnings per share. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date is Wednesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.71%.
ILLEGAL ACTIVITY WARNING: “Sentry Investment Management LLC Has $6.04 Million Position in Thermo Fisher Scientific Inc. (TMO)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/02/13/sentry-investment-management-llc-has-6-04-million-position-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.